# Junta clínica — PT-pseudo_562159dc2cc6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_562159dc2cc6",
  "pid": "PT-pseudo_562159dc2cc6",
  "task": 1,
  "psa": 9.9,
  "age": 48,
  "months": 3,
  "pirads": "2",
  "psad": 0.19,
  "psav": 0.31,
  "psap": 6.7,
  "vol": 50.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.6607788,
  "medhx": "Hypertension",
  "meds": "lisinopril, metoprolol",
  "notes": "PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "73 kg",
    "height": "180 cm",
    "bmi": "22.5",
    "bp": "137/81 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (35 pack-yr, quit 2016)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment."
    },
    {
      "s": "History",
      "t": "Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Sleep clinic — suspected obstructive sleep apnoea",
    "Pain clinic — chronic shoulder pain"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_562159dc2cc6
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 48-year-old male
  - PSA: 9.9 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6607788 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.

Vitals: weight 73 kg, height 180 cm, BMI 22.5, BP 137/81 mmHg, HR 81 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2016).

Chief complaint: Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment.

History: Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability.

Physical examination: Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected.

Patient info: retired postal worker; Married; Lives alone; adult daughter is primary contact.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Sleep clinic — suspected obstructive sleep apnoea; Pain clinic — chronic shoulder pain.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.26
  uncertainty  +/- 0.19 epistemic (95% band 0.00-0.63); among patients I cannot tell apart the outcome was 0.83 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 1 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 48 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 9.9 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 50 mL (1% of my signal; from log_vol, vol) · PSA density = 0.19 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.66 (1% of my signal; from cspca) · PI-RADS = 2 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 2
  important  prior biopsy = None
  noted      age = 48 · DRE = Normal · PSA = 9.9 ng/mL · prostate volume = 50 mL · PSA density = 0.19 · comorbidity = 1 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 23 men I have seen in this same situation (None prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.71: PI-RADS 2, PSA 9.8, PSAD 0.073, age 54, DRE Normal -> DEFER (clear). He wrote: "Young increases importance of longterm risk assessment. BPH, low PSAd, benign MRI, no family history increases confidence to avoid biopsy at this point."
  2. distance 4.29: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"
  3. distance 4.32: PI-RADS 4, PSA 14.0, PSAD 0.734, age 47, DRE Nodus -> BIOPSY (clear). He wrote: "PIRADS 4 with high PSA-density needs biopsy"

PRECEDENT: DEFER (weighted vote 0.22 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = None · family history = not opened (0 of 91) · age = 48 · DRE = Normal · prostate volume = 50 mL · PSA density = 0.19 · PI-RADS = 2
  noted      PSA = 9.9 ng/mL · csPCa probability = 0.66
  not used   comorbidity
CONFIDENCE: clear — the precedents agree (0.22) and the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 23 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 2
  important  age = 48 · PSA = 9.9 ng/mL
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Normal · prostate volume = 50 mL · PSA density = 0.19 · comorbidity = 1 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that for patients with a PI-RADS score of 2, the recommendation is to omit biopsy and offer PSA monitoring, especially when the PSA density is low and there is no family history. The guideline states: "Omit biopsy and offer PSA monitoring when MRI is negative (i.e. PI-RADS $\le$ 2), and clinical suspicion of PCa is low (PSA density < 0.20 ng/mL/cc and no family history)."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of NO BIOPSY is in direct alignment with the guideline's recommendation for a PI-RADS 2 finding when risk factors are low. The guideline suggests that the variable 'PI-RADS = 2' is context, and the guideline makes the variable 'PSA density < 0.20 ng/mL/cc and no family history' decisive for this decision. The guideline requires the fact that the patient's PSA density is $0.19 \text{ ng/mL}^2$ and that there is no family history.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: None - the guideline suggests omitting biopsy when MRI is negative (PI-RADS $\le$ 2) and clinical suspicion is low.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: $0.31 \text{ ng/mL/yr}$ - this trend is noted, but the guideline focuses more on static metrics like PSA density for this decision.
laboratory_results - the PSA density: $0.19 \text{ ng/mL}^2$ - this value is critical as it is used in the guideline's risk-adapted matrix.
family-history anamnesis - the family history of prostate cancer: not opened - the guideline explicitly states that the absence of a family history is a factor in omitting biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case strongly points towards deferral based on the PI-RADS 2 finding and the low PSA density, aligning with the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the mpMRI prose regarding lesion size, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA velocity ($0.31 ext{ ng/mL/yr}$) and how does it factor into the decision?
  previous_notes (get_previous_notes) -> What is the prior biopsy status, and is there a surveillance protocol in place?

On the plan itself: Dropped 2 question(s) that asked for a value already printed on the panel: "What should be done given the PI-RADS = 2 finding?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate MRI | Spaarne Gasthuis, Haarlem | 20 January 2025
What is the mpMRI prose regarding lesion size, extraprostatic extension, and comparison against an earlier study?
Volumetric assessment yields a gland size of 50.0 mL. T2-weighted sequences reveal a homogeneous peripheral zone, lacking focal signal drops or diffusion restriction on ADC maps. Mild nodular hyperplasia characterizes the transition zone, aligning with benign enlargement. Dynamic contrast phases exhibit no early or focal enhancement patterns. Seminal vesicles maintain normal caliber and signal intensity. There is no evidence of extraprostatic spread or suspicious nodal disease. The bladder wall presents smoothly, free of diverticula. IMPRESSION: Benign prostatic enlargement measuring 50.0 mL. No PI-RADS 3 or higher lesion identified. PI-RADS 2. PSA density: 0.19 ng/mL/mL. csPCa predicted probability 0.6607788.

psa_trend
What is the PSA velocity ($0.31 ext{ ng/mL/yr}$) and how does it factor into the decision?
The PSA velocity is $0.31 \text{ ng/mL/yr}$. The guideline focuses more on static metrics like PSA density for this decision.

previous_notes
What is the prior biopsy status, and is there a surveillance protocol in place?
The prior biopsy status is None. There is no surveillance protocol in place.

WHAT I DID NOT OPEN
family-history anamnesis, because the guideline explicitly states the absence of a family history is a factor in omitting biopsy.

WHAT THIS SUPPORTS
FOR sampling this patient now
csPCa predicted probability $0.6607788$ (from the panel)
AGAINST sampling this patient now
PI-RADS = 2 (from the panel)

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 9.90 ng/mL over 3 points spanning 11 months; velocity +7.52 ng/mL per year; doubling time about 6 months.
PROJECTION at 6 months: 16.0 ng/mL, conformal 95% band 4.6-55.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 9.9 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.20
  uncertainty  +/- 0.14 epistemic (95% band 0.00-0.47), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 2 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 9.9 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 50 mL (4% of my signal; from log_vol, vol) · PSA density = 0.19 (0% of my signal; from psad_calc) · comorbidity = 1 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.26  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.20  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.22  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_2; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> noted
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:IMP E2:—                  -> not_used (raised from noted by the board)
  age          48                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:IMP E2:—              -> not_used (raised from noted by the board)
  psa          9.9 ng/mL                    E1:not E3:not cohort:not library:not E2:not          -> important
  vol          50 mL                        E1:not E3:not cohort:not library:IMP E2:—            -> noted
  psad         0.19                         E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.66                         E1:not E3:— cohort:— library:not E2:—                -> not_used
  pirads       2                            E1:not E3:IMP cohort:DEC library:IMP E2:—            -> decisive
  comorbidity  1 on the problem list        E1:IMP E3:not cohort:not library:— E2:—              -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) appear to have answered the questions posed by the moderator, as the Registrar reported findings for each document.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY. Specifically, the cohort criterion (PI-RADS $\le$ 2) fired, which is the rule that led to the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
There were no open questions recorded by the moderator, so this step is not applicable.

WHAT CARRIES WEIGHT, AND WHY
<PI-RADS>: 2: decisive because the EXPERT-COHORT rule fired based on this finding, leading to the panel's decision. I agree with the PANEL-PROTOCOL's level of decisive.
<PSA density>: 0.19 ng/mL/mL: noted because the EAU guideline explicitly used this value to support the deferral recommendation. I agree with the PANEL-PROTOCOL's level of noted.
<prior biopsy>: None: decisive because the EXPERT-STRUCTURED and EXPERT-FUSION experts weighted this as decisive, and the panel protocol noted it as 'None recorded'. I agree with the PANEL-PROTOCOL's level of decisive.
My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with the panel's recommendation of NO BIOPSY, as the evidence retrieved directly supports the cohort criterion that dictated this outcome.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

48y male, PSA 9.9 ng/mL, PSAD 0.19, PI-RADS 2, biopsy-naive. Defer biopsy as PI-RADS 2 with low PSAD suggests monitoring; the PSA is only modestly raised. Re-check PSA and biopsy only if it continues to rise.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
